Know Cancer

or
forgot password

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol


N/A
18 Years
N/A
Not Enrolling
Both
Solid Tumors

Thank you

Trial Information

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol


Inclusion Criteria:



- Prior SU011248 Protocol.

- Eligible to continue SU011248 treatment.

Exclusion Criteria:

- Uncontrolled CNS metastasis.

- Unfit to receive SU011248.

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Duration of Treatment

Outcome Time Frame:

Baseline up to Day 28 after last dose of study treatment

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A6181030

NCT ID:

NCT00798889

Start Date:

March 2004

Completion Date:

December 2011

Related Keywords:

  • Solid Tumors
  • Solid tumors

Name

Location

Pfizer Investigational SiteBirmingham, Alabama  35205
Pfizer Investigational SiteBlendora, California  91740
Pfizer Investigational SiteDetroit, Michigan  48201
Pfizer Investigational SiteRochester, Minnesota  55905
Pfizer Investigational SiteCincinnait, Ohio  45236
Pfizer Investigational SiteBronx, New York  10461
Pfizer Investigational SiteHouston, Texas  77030
Pfizer Investigational SiteAurora, Colorado  80012
Pfizer Investigational SiteCarmel, Indiana  46032
Pfizer Investigational SiteNorth Adams, Massachusetts  01247
Pfizer Investigational SiteColumbia, Missouri  65201
Pfizer Investigational SiteSanta Fe, New Mexico  87505
Pfizer Investigational SiteAsheville, North Carolina  28801
Pfizer Investigational SiteKingston, Pennsylvania  18704-5535
Pfizer Investigational SiteEasley,, South Carolina  29640
Pfizer Investigational SiteMilwaukee, Wisconsin  53215
Pfizer Investigational SiteBristol, Tennessee  37620